SCHEMBL6469210

SCHEMBL6469210

C[C@H](CCc1ccc(C(N)=O)nc1)NC1CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VNN1 O95497 1/20 0.41
HRH3 Q9Y5N1 3/20 0.40
ACACB O00763 5/20 0.39
MASP2 O00187 1/20 0.39
OPRM1 P35372 1/20 0.38
OPRD1 P41143 1/20 0.38
OPRK1 P41145 1/20 0.38
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 1/20 0.38
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
MAPT P10636 1/20 0.38
PKM P14618 1/20 0.38
ALOX15 P16050 1/20 0.38
TSHR P16473 1/20 0.38
NFKB1 P19838 1/20 0.38
THPO P40225 1/20 0.38
BLM P54132 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6471057 1.00 VNN1 (0.41) VNN1HRH3ACACBMASP2OPRM1
SCHEMBL6470916 1.00 VNN1 (0.41) VNN1HRH3ACACBMASP2OPRM1
SCHEMBL5133076 0.95 ACACB (0.39) VNN1HRH3ACACBMASP2OPRM1
SCHEMBL6470831 0.83 VNN1 (0.42) VNN1ACACBMASP2OPRM1OPRD1
SCHEMBL5044954 0.82 VNN1 (0.41) VNN1HRH3ACACBMASP2OPRM1
SCHEMBL5133518 0.81 DPP4 (0.44) VNN1ACACBMASP2OPRM1OPRD1
SCHEMBL6471059 0.80 SLC6A4 (0.41) ACACBMEN1ALDH1A1KMT2ASLC6A4
SCHEMBL6469213 0.80 SLC6A4 (0.41) ACACBMEN1ALDH1A1KMT2ASLC6A4
SCHEMBL6470917 0.80 SLC6A4 (0.41) ACACBMEN1ALDH1A1KMT2ASLC6A4
SCHEMBL5132091 0.80 DPP4 (0.43) VNN1ACACBOPRM1OPRD1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050107381-A1 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders PFIZER, INC. 2005-05-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107381-A1 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders APP, BACE1, SNCA VNN1 3874/4885HRH3 296/4885ACACB 2503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.